Representative Patents and Published Applications

  • U.S. Patent 10,619,211 – Methods Using DNA Methylation for Identifying a Cell or a Mixture of Cells for Prognosis and Diagnosis of Diseases, and for Cell Remediation Therapies (Assignees: Brown University; The Regents of the University of California)
  • U.S. Patent 10,619,155 – Methods for Labeling and Manipulating a Cellular Circuit (Assignee: Brown University)
  • U.S. Patent 10,488,396 – Apparatus, Method, System for the Determination of the Aggregation Rate of Red Blood Cells (Assignee: Alcor Scientific, Inc.)
  • U.S. Patent 10,448,877 – Methods for Prediction and Early Detection of Neurological Events (Assignees: Brown University; The General Hospital Corporation; The U.S. Government as Represented by the Department of Veterans Affairs)
  • U.S. Patent 10,441,160 – Method and System for Classifying Optic Nerve Head (Assignee: Delphinium Clinic, Ltd.)
  • U.S. Patent 10,274,477 – High-Speed Molecular Diagnostics (Assignee: Brown University)
  • U.S. Patent Application 2020/0129115 – Improved Diagnostic Instrument and Methods (Assignees: Brown University; Women & Infants Hospital of Rhode Island)
  • U.S. Patent Application 2019/0015419 – Deuterated Analogs of Etifoxine, Their Derivatives and Uses Thereof (Assignee: Gaba Therapeutics Inc.)
  • U.S. Patent 9,339,557 and 9,095,613 – Photosensitizer-Metal Nanoparticle Complex and Composition Containing the Complex for Photodynamic Therapy or Diagnosis (Assignee: National Cancer Center)°
  • U.S. Patent 8,883,417 – Clinically Intelligent Diagnostic Methods Utilizing Micromixers Disposed in Wells (Assignee: Intelligent Medical Devices, Inc.)°
  • U.S. Patent 8,877,909 – Optimized Oligonucleotides and Methods of Using Same for the Detection, Isolation, Amplification, Quantitation, Monitoring, Screening, and Sequencing of Group B Streptococcus (Assignee: Intelligent Medical Devices, Inc.)°
  • U.S. Patent 8,758,996 – Optimized Probes and Primers and Methods of Using Same for the Binding, Detection, Differentiation, Isolation and Sequencing of Influenza A; Influenza B; Novel Influenza A/H1N1; and a Novel Influenza A/H1N1 RNA Sequence Mutation Associated with Oseltamivir Resistance (Assignee: Intelligent Medical Devices, Inc.)°
  • U.S. Patent 8,088,572 – Polynucleotides for the Detection of Escherichia coli O157:H7 and Escherichia coli O157:NM Verotoxin Producers (Assignee: AES Chemunex S.A.)°
  • U.S. Patent 7,998,679 – Devices and Methods for Diagnosis of Susceptibility to Diseases and Disorders (Assignee: Intelligent Medical Devices, Inc.)°
  • U.S. Patent 7,833,744 – Methods to Evaluate Cytochrome P450 2C19 Isoenzyme Activity Using a Breath Test (Assignee: Cambridge Isotope Laboratories, Inc.)°
  • U.S. Patent 7,754,913 – Synthesis of Isotopically Labeled Alpha-Keto Acids and Esters (Assignee: Cambridge Isotope Laboratories, Inc.)°
  • U.S. Patent 7,658,910 – Preparation of Radiolabelled Haloaromatics via Polymer-Bound Intermediates (Assignee: The University of Western Ontario)°
  • U.S. Patent 7,622,250 – Clinically Intelligent Diagnostic Devices and Methods (Assignee: Intelligent Medical Devices, Inc.)°
  • U.S. Patent 7,556,794 – Pendant Fatty Acid Imaging Agents (Assignee: Molecular Insight Pharmaceuticals, Inc.)°
  • U.S. Patent 7,381,745 – Ligands for Metabotropic Glutamate Receptors and Inhibitors of NAALADase (Assignee: Georgetown University)°
  • U.S. Patent 7,335,347 – Methods for Purifying Radiolabelled Compounds (Assignee: McMaster University)°
  • U.S. Patent 7,317,103 – Imaging Agents for Diagnosis of Parkinson’s Disease (Assignee: Molecular Insight Pharmaceuticals, Inc.)°
  • U.S. Patent 6,270,749 – Use of Texaphyrin in Ocular Diagnosis and Therapy (Assignee: Pharmacyclics Inc.)°

°Denotes representations that were handled by a member of Adler’s Life Sciences team prior to joining Adler Pollock & Sheehan, P.C.

Back to Top